alessandro
sett
san
diego
usa
bioinformat
immunolog
approach
understand
interact
infecti
pathogen
host
present
state
art
strategi
recent
develop
technolog
support
prevent
treatment
new
emerg
infecti
diseas
gave
detail
overview
new
approach
identif
comparison
viral
molecular
structur
recogn
murin
nonprim
human
immun
system
major
focu
work
develop
public
resourc
immun
epitop
databas
iedb
provid
quick
access
key
inform
immun
epitop
data
iedb
avail
research
round
world
main
aim
acceler
develop
improv
vaccin
francesco
marincola
bethesda
usa
look
immunolog
constant
reject
biolog
process
result
allograft
cancer
reject
autoimmun
tissu
damag
infect
trigger
distinct
mechan
howev
independ
trigger
event
ex
vivo
observ
identifi
similar
molecular
footprint
associ
resolut
pathogen
process
cancer
acut
pathogen
infect
tissu
damag
organ
failur
allograft
reject
autoimmun
suggest
immunolog
constant
reject
requir
immunemedi
tissu
destruct
footprint
includ
interferon
stimul
gene
isg
activ
innat
immun
effector
function
ief
isg
appear
necessari
suffici
induct
immunologicallymedi
tissu
destruct
ief
repres
valuabl
biomark
termin
immunedifferenti
requir
elimin
unwant
tissu
prototyp
exampl
recent
describ
marincola
group
studi
mechan
lead
regress
basal
cell
carcinoma
treatment
tolllik
receptor
agonist
imiquimod
blind
random
placebocontrol
studi
strong
activ
ief
seen
particularli
tumor
treat
optim
administr
schedul
observ
reconcil
ambigu
role
attribut
inflamm
cancer
progress
chronic
inflamm
promot
tumor
growth
acut
inflamm
requir
cancer
reject
paolo
casali
irvin
ca
usa
immunoglobulin
somat
hypermut
class
switch
dna
recombin
outlin
current
knowledg
somat
hypermut
immunoglobulin
ig
gene
somat
hypermut
shm
class
switch
dna
recombin
csr
central
matur
antibodi
autoantibodymedi
respons
shm
csr
affect
twostep
process
dna
lesion
initi
activationinduc
cytidin
deaminas
aid
ii
lesion
repair
combin
intervent
dna
replic
repair
factor
includ
mismatch
repair
mmr
protein
transles
dna
synthesi
tl
polymeras
aid
tl
polymeras
crucial
shm
induc
b
cell
trigger
stimuli
bcell
receptor
crosslink
engag
polymeras
togeth
mmr
protein
dna
replic
repair
factor
could
assembl
form
multimolecular
complex
mutasom
site
dna
lesion
paolo
casali
describ
concept
within
context
exist
vivo
vitro
find
discuss
integr
mechanist
model
shm
csr
hansgeorg
rammense
tuebingen
germani
predict
mhc
ligand
exampl
appli
immunoinformat
larg
number
allel
variant
human
leukocyt
antigen
hla
immunoinformat
use
predict
new
ligand
natur
present
given
hla
molecul
combin
immunoinformat
proteom
method
eg
mass
spectrometri
lead
character
ligandom
complet
set
hla
ligand
given
individu
applic
knowledg
design
therapeut
vaccin
tumor
prof
rammense
describ
ligandom
studi
divers
famili
b
definit
supermotif
glutam
acid
aspart
acid
posit
two
hydrophob
amino
acid
cterminu
ligand
howev
within
sever
hundr
superfamili
ligand
peptid
found
bind
one
allel
limit
simpl
motif
predict
alleleor
supertypespecif
ligand
demonstr
sophist
comput
solut
need
studi
divers
hla
famili
ultim
goal
ie
assembl
nearcomplet
ligandom
combin
sophist
comput
predict
experiment
valid
instrument
prevent
therapi
major
diseasescanc
infecti
diseas
autoimmun
laszlo
patthi
budapest
hungari
gene
predict
mispredict
avail
total
genom
sequenc
nourish
notion
comput
gene
identif
fairli
easi
task
convers
raw
genom
sequenc
data
biolog
knowledg
howev
far
trivial
therefor
predict
subject
stringent
qualiti
control
dr
patthi
point
current
percentag
incorrectlyincomplet
predict
gene
within
wellstudi
human
genom
error
rate
much
higher
genom
earlier
stage
annot
speaker
illustr
exampl
key
step
mispr
approach
weed
invalid
mislead
predict
exampl
misannot
detect
known
subcellular
local
predict
protein
match
molecular
address
eg
signal
sequenc
absent
extracellular
protein
similarli
mispr
programm
issu
warn
predict
protein
contain
abnorm
domain
combin
contain
domain
show
major
deviat
common
size
domainfamili
summari
dr
patthi
present
clear
case
necess
detect
gene
mispredict
whose
extent
often
underestim
abil
mispr
strategi
spot
abnorm
mispredict
protein
ensur
place
gene
annot
effici
tool
qualiti
control
list
symposia
confer
immunogenom
immunom
gene
network
system
biolog
immun
system
model
comput
artifici
immun
system
biologicallyinspir
paradigm
immun
databas
databas
tool
intellig
vaccin
design
immunogen
therapi
genet
redirect
lymphocyt
pharmacogenom
drug
develop
immun
diseas
deciph
immun
intracellular
signal
pathway
oncogenom
antitumor
immunom
autoimmun
autoimmun
immunom
pathogen
analysi
infect
genom
predict
immunepathogen
interact
allergi
genom
allergom
allergen
immunom
mast
cell
basophil
genom
immunecellom
neuroimmuno
genom
inflamm
genom
symp
gene
network
system
biolog
immun
chairperson
stephan
beck
satoru
miyano
symposium
compris
five
plenari
lectur
address
core
aspect
system
biolog
includ
genom
proteom
bioinformat
stephan
beck
cambridg
uk
open
symposium
brief
review
grow
field
immunogenom
discuss
recent
advanc
differ
set
genom
data
combin
integr
epi
genet
approach
common
diseas
provid
miss
link
genet
diseas
environ
chack
yung
yu
ohio
usa
focus
caus
consequ
copi
number
variat
cnv
autoimmun
diseas
present
studi
demonstr
cnv
polymorph
complement
compon
contribut
suscept
lupu
erythematosu
sle
timothi
ravasi
la
jolla
usa
introduc
concept
network
analysi
demonstr
power
conjunct
experiment
data
cap
analysi
gene
express
cage
infer
transcript
network
macrophag
inflammatori
immun
respons
bernhard
homey
sseldorf
germani
report
lesson
learnt
global
analysi
chemokin
famili
less
protein
involv
regul
leukocyt
traffick
atop
dermat
hous
dustinduc
allergi
among
mani
clinic
import
phenotyp
associ
chemokinemedi
immun
respons
laszlo
takac
debrecen
hungari
discuss
potenti
biomark
tool
monitor
drug
efficaci
clinic
trial
use
shotgun
immunis
follow
antibodymedi
proteom
plasma
proteomespecif
librari
monoclon
antibodi
gener
expect
lead
develop
novel
clinic
assay
satoru
miyano
tokyo
japan
present
overview
comput
approach
system
biolog
global
network
remain
comput
intract
less
complex
network
success
appli
comput
new
drug
target
develop
cell
illustr
interact
softwar
model
simul
cellular
interact
repres
import
step
toward
enabl
biomed
scientist
explor
har
power
network
analysi
close
lectur
given
suresh
jivan
gadher
nyon
switzerland
describ
commerci
solut
biomark
discoveri
includ
proteomelab
igi
partit
system
symp
system
model
comput
immunolog
chairperson
soren
brunak
sandor
pongor
system
biolog
approach
immunolog
strive
bridg
gap
datadriven
disciplin
genom
bioinformat
datapoor
model
network
biolog
simul
symposium
present
seri
snapshot
along
pathway
open
lectur
sandor
pongor
triest
itali
describ
evolut
robust
network
topolog
gave
outlin
applic
network
model
biolog
system
quantit
model
immun
respons
present
phil
hodgkin
melbourn
australia
describ
stochast
cellular
calculu
model
massimo
bernaschi
rome
itali
present
result
agentbas
simul
datadriven
approach
present
francisca
sanchezjimenez
malaga
spain
describ
knowledg
base
integr
data
model
biogen
amin
avbmbqumaesasp
shoba
raganathan
sidney
australia
present
structur
immunoinformat
studi
mhcpeptid
complex
applic
autoimmun
disord
pemphigu
vulgari
two
short
talk
focuss
practic
applic
miriam
goldberg
provid
usa
present
result
use
bioinformat
tool
predict
class
ii
hlabind
peptid
francesco
pappalardo
catania
itali
present
comput
model
optim
vaccin
schedul
present
soren
brunak
lyngbi
denmark
sum
session
broad
summari
comput
analysi
spatiotempor
chang
cell
cycl
symp
artifici
immun
system
biologicallyinspir
paradigm
chairperson
santo
motta
jon
timmi
session
six
invit
paper
three
short
present
session
cover
wide
spectrum
research
activ
rang
comput
model
variou
aspect
immun
system
exploit
immun
system
concept
engin
applic
wide
spectrum
inde
first
topic
symposium
exploit
immunolog
concept
inspir
engin
solut
softwar
hardwar
jon
timmi
york
uk
two
system
present
symposium
one
track
object
virtual
world
rgi
cserey
budapest
hungari
identifi
failur
autom
teller
machin
laszlo
prokai
fort
worth
usa
howev
also
discuss
better
interact
engin
immunologist
need
advanc
rang
applic
interact
facilit
use
comput
model
major
topic
symposium
studi
immunolog
problem
number
insight
present
use
comput
model
studi
variou
aspect
immun
system
duccio
cavalieri
florenc
itali
comput
model
cancer
growth
develop
valid
experiment
result
santo
motta
catania
itali
comput
model
allow
research
ask
question
answer
pure
experiment
vivo
approach
comput
predict
appli
studi
epitopebas
vaccin
natalia
tarnovitski
freund
telaviv
israel
work
tcell
epitop
analys
algorithm
map
epitop
sar
coronaviru
spike
protein
potenti
epitop
identifi
target
vaccin
design
model
nk
cell
develop
repertoir
format
present
ramit
mehr
ramatgan
israel
model
predict
differ
repertoir
develop
happen
differ
condit
support
experiment
evid
hassan
tadjbakhsh
tehran
iran
model
approach
propos
analysi
inform
process
immun
system
languag
short
peptid
elegantli
shown
littl
overlap
set
uniqu
self
peptid
foreign
peptid
rob
j
de
boer
utrecht
netherland
session
emphasis
great
deal
potenti
synergi
combin
studi
natur
artifici
immunolog
symp
immun
databas
databas
tool
chairperson
mariepaul
lefranc
vladimir
brusic
immunolog
databas
databas
tool
repres
essenti
resourc
studi
immun
system
nearli
thirti
databas
focus
variou
aspect
immun
system
cite
nar
databas
list
wwwoxfordjournalsorgnardatabasecap
imgt
immunoinformat
page
imgtcinesfr
histor
immunolog
databas
focus
inform
relat
gene
protein
immun
system
immunoglobulin
major
histocompat
complex
mhc
molecul
immunopolymorph
integr
data
multipl
sourc
combin
bioinformat
analysi
tool
enabl
autom
analysi
knowledg
discoveri
databas
vladimir
brusic
brisban
australia
present
basic
concept
data
wareh
datamin
immunolog
discoveri
identif
gene
protein
immun
system
difficult
complex
immun
interact
immun
system
product
detect
genom
proteom
studi
immun
system
tissu
use
literatur
mine
csaba
ortutay
tamper
finland
present
databas
call
immunom
contain
sequenc
annot
inform
gene
protein
involv
immun
function
human
leukocyt
antigen
hla
human
mhc
gene
show
largest
variat
human
gene
refer
data
set
eight
hlahomozyg
type
haplotyp
compil
annot
mhc
class
region
chromosom
richard
gibson
cambridg
uk
present
mhc
haplotyp
project
studi
diseas
loci
within
mhc
region
imgthla
databas
centralis
repositori
factor
hla
system
defin
hla
nomenclatur
committe
immun
polymorph
databas
ipd
contain
inform
known
polymorph
gene
immun
system
two
resourc
present
steven
marsh
london
uk
descript
imgt
intern
immunogenet
inform
system
refer
immunogenet
immunoinformat
present
mariepaul
lefranc
montpelli
franc
imgt
standard
base
imgtontolog
imgt
compris
five
databas
analysi
tool
page
web
resourc
sequenc
genet
imgt
collier
de
perl
structur
immunoglobulin
ig
tcell
receptor
tr
mhc
relat
protein
immun
system
rpi
belong
igsf
mhcsf
matthew
davi
compton
uk
present
databas
bcell
tcell
epitop
antijen
offer
insight
structur
perspect
predict
immun
epitop
final
adriano
mari
rome
itali
present
allergom
databas
integr
experiment
literatur
clinic
data
allergen
analyt
tool
immunolog
databas
bioinformat
tool
necessari
effici
analysi
combinatoriallyrich
immunolog
data
symp
intellig
vaccin
design
chairperson
tom
august
eva
rajnavolgyi
contemporari
vaccin
develop
hold
promis
protect
us
infecti
diseas
cancer
allergi
autoimmun
formid
challeng
field
still
remain
includ
select
adequ
tand
bcell
epitop
target
vaccin
formul
elicit
desir
type
immun
respons
deliveri
system
enorm
combinatori
complex
vaccin
develop
call
intellig
vaccin
design
combin
immunoinformat
molecular
biolog
genom
classic
vaccinolog
nikolai
petrovski
adelaid
australia
introduc
basic
concept
review
current
trend
field
j
thoma
august
baltimor
usa
present
work
combin
immunoinformat
method
predict
tcell
epitop
tcell
epitop
hotspot
analysi
viral
divers
identif
conserv
motif
lamptarget
dna
vaccin
preclin
studi
transgen
mice
clinic
trial
shown
promis
result
viral
hiv
influenza
dengu
cancer
immunotherapi
eszter
nagi
vienna
austria
introduc
concept
human
pathogen
antigenom
select
vaccin
candid
strategi
util
full
genom
coverag
serolog
type
identif
antigen
bacteri
pathogen
highthroughput
vitro
valid
reli
gene
conserv
immunogen
extracellular
local
induct
function
antibodi
help
identifi
novel
highli
conserv
antigen
aureu
pheumonia
pyogen
agalactia
eva
lgyi
debrecen
hungari
discuss
use
dendrit
cell
dc
vaccin
adjuv
prophylact
therapeut
set
work
show
dc
display
subsetspecif
combin
transmembran
cytosol
pattern
recognit
receptor
determin
involv
divers
signal
pathway
transcript
regul
dc
program
activ
synergist
signal
pathway
act
potent
adjuv
camil
locht
lill
franc
present
studi
mechan
interact
tuberculosi
nonprofession
phagocyt
latent
infect
heparinbind
hemagglutinin
hbha
major
factor
involv
extrapulmonari
dissemin
establish
latenc
hbhacoat
microbead
penetr
epitheli
endotheli
cell
layer
induc
strong
tcell
respons
laszlo
radvanyi
houston
usa
discuss
tumor
microenviron
factor
limit
success
tcellbas
therapi
includ
role
immunosuppress
cytokin
activ
tregulatori
cell
defect
antigenpres
cell
discuss
util
adopt
cell
transfer
therapi
use
tumor
infiltr
lymphocyt
use
number
experiment
approach
hanna
rokita
krakow
poland
present
work
develop
test
peptidebas
vaccin
therapi
neuroblastoma
strategi
involv
peptid
mimet
gangliosid
preclin
studi
mous
model
analysi
patient
sera
reactiv
select
peptid
member
ann
de
groot
laboratori
provid
usa
present
immunom
approach
develop
vaccin
smallpox
tularemia
h
pylori
approach
involv
combin
comput
screen
potenti
tcell
epitop
bind
assay
follow
experiment
valid
elispot
assay
symp
immunogen
therapi
chairperson
martin
zenk
richard
goldsbi
zenk
aachen
germani
set
stage
report
genom
approach
dendrit
cell
dc
biolog
emerg
evid
suggest
dc
develop
popul
progenitor
cell
via
pathway
differ
convent
pathway
produc
lymphoid
myeloid
cell
dc
also
develop
vaccin
zenk
report
smart
contrast
agent
monitor
dc
locat
function
vivo
number
tumorspecif
tumorassoci
antigen
use
target
immuno
antitumor
therapi
includ
cn
baxevani
athen
greec
report
ongo
studi
aim
overcom
toler
neu
bear
tumor
activ
immun
peptid
ii
adopt
transfer
specif
cytotox
lymphocyt
ctl
iii
transfer
genet
modifi
ctl
express
epitop
iv
target
sirna
molecul
g
budapest
hungari
present
data
cytokin
produc
cancer
vaccin
mous
glioma
brain
model
combin
local
radiotherapi
immun
reaction
elicit
vivo
analyz
found
vaccin
induc
activ
ctl
deplet
abolish
antitumor
effect
j
yoshida
nagoya
japan
report
novel
formul
cation
liposom
contain
interferon
ifn
b
gene
therapi
human
glioma
preclin
studi
demonstr
drug
formul
safe
clinic
studi
therapi
involv
surgeri
tumor
resect
follow
stereotact
inject
gene
drug
five
patient
receiv
treatment
promin
observ
effect
ctl
activationther
also
consider
interest
use
immunogen
therapi
suppress
unwant
immun
respons
system
autoimmun
diseas
h
oishi
tsukuba
japan
present
data
use
tristetraprolin
ttp
physiolog
regul
tnfa
gmcsf
product
transgen
model
mrllpr
autoimmun
prone
mice
found
renal
arter
significantli
reduc
mice
suggest
ttp
gene
therapi
potenti
modal
treatment
human
autoimmun
vascul
design
engin
immunoglobulinexpress
construct
anim
major
focu
effort
increas
effici
lower
cost
produc
antibodi
prophylaxi
therapi
varieti
approach
problem
explor
symposium
g
hadlaczki
szege
hungari
describ
ace
system
monoclon
antibodi
product
system
four
element
mammalian
artifici
chromosom
acceptor
site
target
vector
ii
vector
acceptor
site
artifici
chromosom
contain
gene
express
iii
integras
catalyz
sitespecif
recombin
vector
acceptor
site
iv
cho
cell
line
adapt
high
densiti
growth
serumfre
medium
target
transact
artifici
chromosom
approach
permit
gener
cell
line
suitabl
product
research
quantiti
monoclon
antibodi
within
two
month
also
possibl
deriv
clonal
line
express
industryrelev
level
antibodi
polyclon
human
antibodi
long
histori
use
treatment
mani
differ
diseas
howev
antibodi
current
obtain
human
donor
problem
suppli
potenc
standard
solv
problem
variou
technolog
use
creat
genet
engin
anim
synthes
polyclon
human
antibodi
two
model
one
rabbit
bovin
describ
thorey
bernri
germani
report
engin
rabbit
substitut
human
v
j
sequenc
rabbit
equival
larg
tract
rabbit
immunoglobulin
heavi
chain
kappa
light
chain
loci
rabbit
promot
enhanc
recombin
signal
sequenc
unchang
obtain
preferenti
express
human
antibodi
repertoir
engin
anim
cross
strain
rabbit
natur
occur
mutat
greatli
impair
express
rabbit
immunoglobulin
respons
engin
rabbit
immun
defin
antigen
gener
antigenspecif
human
antibodi
respons
r
goldsbi
amherst
usa
describ
gener
clone
cattl
transchromosom
human
artifici
chromosom
hac
bear
entir
human
igh
ig
light
chain
loci
larg
number
humanig
express
hac
transchromsom
cattl
produc
anim
synthes
fulli
human
antibodi
diversifi
repertoir
immunoglobulin
immun
defin
antigen
induc
product
antigenspecif
human
polyclon
antibodi
furthermor
knockout
technolog
publish
permit
deriv
cattl
make
bovin
igh
ig
therebi
allow
gener
cattl
make
human
bovin
antibodi
symp
genet
redirect
lymphocyt
function
chairperson
michael
nishimura
karoli
tihanyi
immunotherapi
repres
promis
treatment
option
patient
malign
viral
infect
among
success
immunotherapi
treatment
option
adopt
transfer
antigen
specif
cell
two
critic
barrier
left
overcom
would
make
adopt
cell
transfer
feasibl
first
sourc
autolog
antigen
specif
cell
need
readili
avail
diseas
patient
second
function
adopt
transfer
cell
must
retain
vivo
first
four
lectur
discuss
genet
modif
cell
provid
sourc
autolog
antigen
specif
cell
diseas
zelig
eshhar
rehovot
israel
present
pioneer
work
chimer
antibodi
receptor
receptor
util
antigen
bind
region
monoclon
antibodi
fuse
signal
domain
fcc
zelig
eshhar
engin
cell
chimer
receptor
capabl
recogn
tumor
cell
vitro
vivo
mhc
unrestrict
fashion
ralph
willemsen
rotterdam
netherland
michael
nishimura
chicago
usa
matthia
theobald
mainz
germani
present
work
use
nativ
cell
receptor
ab
gene
genet
modifi
cell
dr
willemsen
nishimura
describ
studi
influenc
rel
affin
introduc
cell
receptor
target
cell
recognit
examin
describ
cell
receptor
adequ
affin
engin
cell
recogn
tumor
without
need
coreceptor
dr
willemsen
demonstr
cell
receptor
coexpress
chain
neg
cell
enhanc
function
genet
modifi
cell
dr
nishimura
focus
crossreact
cell
receptor
gene
modifi
cell
exploit
target
mutant
antigen
effici
cell
receptor
pair
discuss
dr
theobald
present
result
indic
region
cell
receptor
constant
region
influenc
stabil
cell
receptor
complex
surfac
genet
modifi
cell
enhanc
function
cell
discuss
stanley
nathenson
bronx
usa
kirsten
baken
bilthoven
netherland
dr
nathenson
describ
structurefunct
studi
slam
famili
molecul
provid
insight
enhanc
cell
signal
function
dr
baken
present
result
studi
microarray
analysi
use
examin
effect
immunosuppress
biocid
bi
trinbutyltin
oxid
tbto
immunotoxicogenom
gene
express
profil
thymu
mice
day
exposur
show
tbtoinduc
atrophi
like
caus
inhibit
cell
prolifer
final
hsueht
chu
taichung
taiwan
describ
studi
predict
best
target
immun
therapi
work
would
lead
vaccin
combin
genet
alter
cell
could
improv
function
vivo
summari
symposium
provid
insight
immunogenom
alter
cell
specif
function
improv
qualiti
immun
respons
patient
malign
viru
infect
symp
pharmacogenom
drug
develop
immun
diseas
chairperson
hansjoachim
gabiu
gyorgi
nemeth
function
cytokin
network
vivo
predict
vitro
experi
success
asthma
therapi
predict
map
haplotyp
complex
b
receptor
target
bronchodil
current
approach
identifi
potent
inhibitor
tissu
lectin
involv
immun
diseas
tumor
progress
implic
abc
transport
protein
chemoimmun
innat
protect
effector
branch
toxic
compound
gene
array
technolog
help
identifi
function
aberr
relev
drug
develop
ankylos
spondyl
extent
cytokin
express
improv
recombin
product
question
expertli
address
contribut
symposium
draw
work
condit
mutant
werner
ller
braunschweig
germani
use
teach
audienc
salient
lesson
cellular
origin
cytokin
matter
markedli
vivo
spectrum
effector
function
intriguingli
suscept
lipopolysaccharid
part
control
macrophagederiv
tcelldepend
product
protein
affect
immun
regul
gut
play
measur
role
instanc
dissect
vivo
cytokin
network
thu
requir
systemat
studi
condit
mutant
also
hold
true
emerg
associ
patient
haplotyp
clinic
paramet
asthma
way
sequenc
variat
b
adrenerg
receptor
help
identifi
patient
high
risk
suffer
complic
illumin
stephen
p
peter
winstonsalem
usa
advers
asthma
outcom
reveal
treatment
shortact
bagonist
albuterol
patient
homozyg
arg
receptor
posit
therefor
matter
consider
interest
investig
genotyp
variant
respect
clinic
outcom
work
also
protein
character
further
current
technic
advanc
summar
suresh
jivan
gadher
nyon
switzerland
advanc
drug
develop
target
immun
effector
lectin
famili
review
hansjoachim
gabiu
munich
germani
design
variou
type
chemic
librari
carbohydr
deriv
amino
acid
latter
identifi
glycomimet
peptid
provid
access
fulli
random
array
compound
screen
computerassist
molecular
model
includ
flexibl
ligand
dock
experi
assess
affin
improv
merg
iter
refin
process
reach
optim
level
target
specif
high
level
specif
deliber
avoid
look
chemoimmun
outlin
sarkadi
budapest
hungari
fact
three
major
transport
abc
atpbind
cassett
protein
famili
current
known
expel
around
differ
compound
xenobiot
cell
protect
damag
obviou
challeng
defin
molecular
characterist
innat
defens
system
challeng
identifi
new
target
therapi
rheumat
diseas
present
met
test
chip
technolog
peter
gerg
jr
budapest
hungari
report
experi
rna
obtain
peripher
blood
cell
patient
ankylos
spondyl
dysregul
gene
express
exampl
concern
vascular
endotheli
growth
factor
warrant
follow
last
contribut
symposium
alireza
zamani
hamedan
iran
address
problem
gene
express
clinic
level
recombin
express
aim
improv
yield
cinterferon
signific
increas
report
strictli
control
express
use
cumateregulat
express
cassett
symp
deciph
immun
intracellular
signal
pathway
chairperson
cox
terhorst
laszlo
nagi
cox
terhorst
boston
usa
talk
recent
studi
role
member
slam
famili
immun
receptor
receptor
function
innat
immun
respons
slamf
defect
mice
abnorm
macrophag
function
appear
slam
control
phagosom
matur
doreen
cantreel
dunde
uk
present
data
role
serin
kinas
lymphocyt
serin
one
frequent
modif
cell
one
key
signal
pathway
effector
protein
kinas
act
downstream
diacylglycerol
protein
kinas
c
pkd
control
subcellular
local
class
ii
histon
deacetylas
provid
link
epigenet
control
transcript
antigen
receptor
hana
kovarova
pragu
czech
republ
introduc
system
approach
identif
character
proteom
tlymphoblast
leukemia
cell
line
upon
cdk
inhibitor
control
use
resist
cell
line
success
identifi
sever
protein
might
provid
insight
pathogenesi
diseas
also
provid
new
therapeut
target
jaswind
sethi
cambridg
uk
use
genom
approach
identifi
gene
regul
tnf
alpha
signal
mous
adipocyt
devoid
use
express
profil
identifi
gene
found
link
ceramid
signal
megi
cincinnatti
usa
studi
human
condit
famili
hemophagocyt
lymphohistiocytosi
fhlh
rare
autosom
recess
lifethreaten
immun
disord
often
refer
orphan
diseas
systemat
evalu
contribut
perforin
diseas
phenotyp
identifi
perforin
missens
mutat
partial
matur
class
appar
proteolyt
matur
class
recogniz
form
perforin
class
nagi
debrecen
hungari
use
genom
approach
includ
global
gene
express
profil
identifi
contribut
nuclear
receptor
dendrit
cell
differenti
function
link
activ
peroxisom
proliferatoractiv
receptor
gamma
pparg
increas
retinoid
product
signal
express
data
suggest
chang
lipid
environ
caus
fundament
chang
gene
express
pattern
dendrit
cell
includ
reprogram
lipid
antigen
present
capac
final
marian
l
turner
melbourn
australia
gave
short
talk
new
paramet
cell
prolifer
found
strike
differ
number
cell
divis
variou
signal
induc
constant
stimul
b
cell
lipopolysaccharid
monoclon
antibodi
result
cycl
cell
divis
b
cell
stimul
cpg
dna
underw
divis
symp
oncogenom
antitumor
immunom
chairperson
pierluigi
lollini
jozsef
timar
first
part
symposium
devot
analysi
pattern
gene
express
tumor
signatur
impact
patient
manag
particular
sensit
therapi
predict
prognosi
second
part
dedic
analysi
immun
respons
cancer
maryam
farzad
santa
clara
usa
appli
spectral
karyotyp
sky
arraybas
compar
genom
hybrid
cgh
microarray
gene
express
analysi
variou
softwar
tool
profil
differ
ovari
carcinoma
cell
sensit
resist
cisplatin
identifi
gene
network
present
clear
illustr
need
power
combin
oncogenom
approach
analysi
complex
tumor
phenotyp
like
drug
resist
ondrej
hrusak
pragu
czech
republ
review
statu
gene
express
profil
leukemia
particular
concern
impact
diagnost
present
data
differenti
acut
lymphoblast
leukemia
base
express
conclud
genom
provid
great
discoveri
tool
replac
rather
complement
convent
diagnost
technolog
zsef
budapest
hungari
present
two
interest
case
function
studi
set
motion
microarray
find
melanoma
unexpectedli
found
express
ryanodin
receptor
howev
receptor
appear
function
henc
could
chiefli
diagnost
signific
show
analysi
melanoma
xenotranspl
reveal
metastasisrel
signatur
yield
wide
set
new
target
exploit
drug
therapi
biotherapi
mepur
h
ravindranath
santa
monica
usa
review
tumor
gangliosid
vantag
point
great
experi
field
particular
show
shed
gangliosid
favor
tumor
growth
progress
depress
antitumor
immun
respons
signific
antigangliosid
igm
titer
detect
variou
type
human
cancer
like
prostat
ovarian
carcinoma
melanoma
correl
diseas
stage
thu
repres
potenti
biomark
tumor
progress
barbara
selig
hall
germani
first
gave
concis
comprehens
overview
variou
omic
deal
analysi
spontan
induc
immun
respons
tumor
present
data
immunoproteom
analysi
tumor
antigen
antitumor
immun
respons
induc
renal
cell
carcinoma
transduc
costimulatori
molecul
direct
identif
protein
mass
spectrometri
could
provid
use
insight
cell
activ
also
potenti
target
new
therapi
aim
modul
cell
activ
pierluigi
lollini
bologna
itali
review
concept
cancer
immunoprevent
ie
use
prophylact
vaccin
prevent
tumor
onset
individu
risk
show
vaccin
combin
three
immun
signal
target
antigen
allogen
mhc
interleukin
complet
prevent
aggress
mammari
carcinoma
transgen
mice
induc
helper
cell
cytokin
mainli
gammainterferon
antibodi
final
chiachung
hou
taipei
taiwan
show
galactolipid
plant
use
taiwanes
folk
medicin
immunomodulatori
chemoprevent
activ
senthamil
r
selvan
newport
beach
usa
demonstr
potenti
simultan
measur
variou
blood
cytokin
cell
marker
immunomonitor
cancer
patient
undergo
vaccin
therapi
symp
autoimmun
autoimmun
immunom
chairperson
nikolai
petrovski
tibor
glant
steffen
gay
zurich
switzerland
introduc
current
use
therapi
rheumatoid
arthriti
ra
conclus
despit
novel
strategi
eg
antitnfa
therapi
far
yet
unabl
cure
diseas
present
focus
synovi
fibroblast
sf
ra
patient
intrins
activ
due
express
tolllik
receptor
rasf
respond
tlrligand
cell
produc
potent
inflammatori
chemokin
includ
rant
thu
attract
immun
cell
affect
joint
tibor
glant
chicago
usa
present
anim
model
ra
use
discoveri
diseas
ra
respons
gene
variou
method
genom
screen
dna
protein
microarray
differ
congen
genemanipul
anim
strain
combin
appli
diagnosi
treatment
factor
method
limit
achiev
earli
diagnosi
success
therapeut
applic
polygen
autoimmun
diseas
alison
finnegan
chicago
usa
present
focus
upon
role
b
cell
antibodi
addit
cell
pathogenesi
ra
rarel
anim
model
recent
studi
demonstr
signific
improv
clinic
symptom
patient
treat
rituximab
monoclon
antibodi
deplet
prob
cell
matur
b
cell
plasma
cell
conclud
autoreact
cell
could
synerg
autoantibodi
induct
sever
arthrit
process
autoreact
cell
autoantibodi
requir
arthriti
induct
b
cellmedi
effector
pathway
synergist
contribut
autoimmun
diseas
alter
lymphocyt
signal
threshold
togeth
factor
may
contribut
disrupt
selftoler
system
autoimmun
nikolai
petrovski
adelaid
australia
question
whether
dogma
crept
autoimmun
research
put
research
track
hinder
develop
cure
potenti
dogma
might
includ
idea
autoimmun
state
immun
hyperfunct
cell
autoreact
featur
healthi
individu
autoimmun
diabet
interferon
gamma
depend
condit
diabetesrel
hla
molecul
better
present
diabetogen
selfpeptid
conclud
data
would
suggest
dogma
fact
opposit
truth
thu
autoimmun
like
state
immun
hypofunct
cell
autoreact
common
featur
nonautoimmun
prone
individu
interferon
gamma
play
import
role
autoimmun
protect
diabetesrel
hla
molecul
defect
rather
effici
present
diabetogen
selfpeptid
milan
buc
bratislava
slovakia
present
data
indic
similar
hla
allel
associ
type
diabet
slovak
popul
observ
elsewher
moncef
zouali
pari
franc
outlin
evolv
concept
potenti
patholog
mechan
underli
system
lupu
erythematosu
discuss
alter
lymphocyt
receptor
signal
may
result
persist
highaffin
selfreact
lymphocyt
therebi
togeth
factor
may
contribut
disrupt
selftoler
system
lupu
erythematosu
symp
pathogen
analysi
infect
genom
predict
immunepathogen
interact
chairperson
jenni
ting
matya
sandor
jenni
ting
chapel
hill
usa
describ
discoveri
new
famili
gene
nbdlrr
nucleotidebind
domain
leucin
rich
region
coin
caterpil
famili
also
nod
nlr
famili
conserv
plant
mammal
known
mediat
wide
rang
hostpathogen
detect
plant
matya
sandor
madison
usa
express
epitop
tag
molecul
differ
mycobacteri
locat
data
indic
antigen
locat
mycobacteri
cytoplasm
induc
cell
immun
express
high
level
suggest
evas
mechan
larg
part
mycobacteri
proteom
seen
host
immun
joann
flynn
pittsburgh
usa
discuss
role
tnf
control
granuloma
reactiv
mtb
antitnf
therapi
also
discuss
monkey
model
mtb
mile
davenport
kensington
australia
discuss
preval
public
tcr
ident
tcr
share
among
differ
individu
respons
pathogen
antigen
hiv
gyorgi
abel
burlington
usa
describ
complex
host
respons
hepat
c
viru
hcv
includ
weaken
host
ifnmedi
signal
enhanc
suppressor
cytokin
signal
soc
juli
mcmurri
provid
usa
discuss
insilico
predict
immunogen
epitop
small
pox
tularemia
vaccin
ann
de
groot
provid
usa
discuss
remov
immunogen
epitop
protein
therapeut
valu
kesmir
utrecht
netherland
discuss
integr
comput
predict
made
hostpathogen
interact
use
long
term
hiv
survivor
demonstr
hla
allel
might
target
region
mutat
hiv
sequenc
produc
protect
cell
respons
ousman
hamadoun
ciss
barnako
mali
discuss
profil
cdna
pbmc
obtain
malaria
patient
indic
chang
immun
respons
apoptosi
proinflammatori
gene
symp
allergi
genom
allergom
allergen
immunom
chairperson
heimo
breitened
csaba
szalai
recent
find
allergom
plant
food
pollen
summar
two
speaker
h
breitened
vienna
austria
c
radauer
vienna
austria
plant
allergen
belong
protein
famili
defin
pfam
databas
version
wwwsangeracuksoftwarepfam
sequenc
plant
food
pollen
allergen
wwwallergomeorg
could
alloc
pfam
famili
respect
four
abund
plant
food
allergen
famili
prolamin
cupin
profilin
bet
v
homologu
contain
plant
food
allergen
eleven
promin
pollen
allergen
famili
contain
pollen
allergen
expansin
profilin
calciumbind
protein
repres
major
one
member
protein
famili
conserv
structur
bet
v
homologu
profilin
polcalcin
highli
crossreact
even
origin
taxonom
unrel
plant
adriano
mari
rome
itali
founder
administr
allergom
databas
gave
overview
current
avail
allergen
databas
web
discuss
pro
con
daniel
soeriaatmadja
uppsala
sweden
present
new
motifbas
predict
system
dflap
webbas
server
risk
assess
potenti
allergen
protein
kenji
izuhara
saga
japan
report
search
novel
asthma
relat
gene
microarray
studi
identifi
postn
gene
encod
periostin
gene
bronchial
epitheli
cell
periostin
thought
adhes
molecul
possess
four
fasciclin
domain
characterist
famili
adhes
molecul
csaba
szalai
budapest
hungari
summar
studi
role
geneenvironment
interact
asthma
children
infect
chlamydophila
pneumonia
carri
allel
found
high
risk
develop
asthma
found
associ
chronic
mycoplasma
pneumonia
mp
infect
accord
result
carri
defect
receptor
might
reduc
suscept
asthma
mp
infect
children
compar
children
similar
infect
statu
carri
wild
type
rob
leur
amsterdam
netherland
talk
characterist
novel
histamin
h
receptor
initi
vivo
experi
receptor
antagonist
suggest
role
receptor
inflammatori
condit
andor
pivarcsi
stockholm
sweden
present
studi
associ
atopyallergi
skin
phenotyp
express
interfac
environ
host
cell
constantli
screen
foreign
antigen
symp
mast
cell
basophil
genom
immunecellom
chairperson
franco
falcon
clemen
dahinden
main
focu
dedic
recent
progress
mast
cell
basophil
genom
introductori
talk
ivan
lefkovit
basel
switzerland
highlight
import
combin
transcriptom
proteom
approach
gene
express
studi
combin
two
avoid
potenti
pitfal
present
techniqu
use
standalon
move
gener
conceptu
framework
success
appli
exampl
integr
function
genom
clemen
dahinden
bern
switzerland
show
combin
approach
identifi
two
novel
potenti
mediat
allergi
basophil
granzym
b
retino
acid
mediat
releas
basophil
expos
supernat
mast
cell
activ
igereceptor
crosslink
falu
budapest
hungari
show
cord
bloodderiv
mast
cell
treat
display
chang
express
gene
promin
upregul
cell
immunoglobulin
mucin
domaincontain
protein
downregul
growth
differenti
factor
went
discuss
mast
cellderiv
may
support
growth
melanoma
tumor
peter
valent
vienna
austria
present
potenti
new
target
therapi
mast
cell
leukemia
identifi
genom
high
throughput
screen
technolog
israel
pecht
rehovot
israel
use
rat
mucosaltyp
mast
cell
show
desensit
obtain
excess
prolong
repetit
exposur
stimulu
regul
fcerimedi
signal
induc
two
differ
type
regulatori
process
protein
degrad
via
ubiquitinproteasom
rout
ii
attenu
posit
signal
recruit
neg
control
molecul
eg
franco
falcon
nottingham
unit
kingdom
present
pilot
studi
aim
develop
new
technolog
combin
allergen
protein
microarray
chip
live
purifi
basophil
appli
diagnosi
type
igemedi
allergi
eg
food
allergen
pollen
assay
coupl
divers
power
protein
array
sensit
basophil
ad
new
biolog
dimens
test
tamsyn
crowley
geelong
australia
studi
effect
chicken
aneamia
viru
cav
poultri
cav
viru
caus
immunosuppress
host
import
econom
factor
broiler
flock
studi
present
first
data
whole
genom
chicken
microarray
show
respons
infect
differ
time
point
session
came
close
present
john
hunt
sidney
australia
look
effect
gene
express
mous
bone
marrowderiv
mast
cell
mbmmc
treatment
induc
chang
express
gene
secret
extracellular
space
gene
known
role
inflamm
symp
neuroimmuno
genom
chairperson
zsuzsa
fabri
judit
szelenyi
socrat
tzarto
number
new
result
therapeut
approach
present
symposium
neuroimmunogenom
cluster
around
molecular
background
predict
therapi
neuroinflammatori
autoimmun
diseas
central
role
inflamm
develop
cn
diseas
present
suggest
common
cellular
target
epilepsi
lp
induc
inflamm
reaction
thalamocort
system
budapest
hungari
role
dendrit
cell
target
infecti
immunomodul
discuss
potenti
novel
therapeut
inflammatori
cn
diseas
zsuzsa
fabri
madison
usa
demonstr
dendrit
cell
migrat
brain
cervic
lymph
node
initi
antigen
specif
cell
activ
home
cn
activ
antigenspecif
cell
accumul
cn
cognat
antigen
contain
traumat
injuri
site
contribut
antigen
deposit
cn
infect
traumat
injuri
brain
novel
concept
also
present
stimulusdepend
immunomodul
advers
immunomodulatori
effect
badrenerg
receptor
demonstr
inflammatori
mediat
product
accompani
parallel
chang
activ
mapk
judit
budapest
hungari
recognit
offer
new
perspect
drug
develop
inflammatori
autoimmun
diseas
sergio
baranzini
san
francisco
usa
two
new
antigenspecif
approach
present
suitabl
studi
treatment
myasthenia
gravi
socrat
tzarto
athen
greec
first
approach
base
fact
fab
fragment
antiachr
monoclon
antibodi
mab
pathogen
protect
achr
pathogen
activ
intact
mg
antibodi
second
approach
select
deplet
patient
plasma
antiachr
autoantibodi
construct
immunoadsorb
column
carri
recombin
achr
fragment
anoth
known
autoimmun
diseas
multipl
sclerosi
ms
differ
strategi
predict
model
respons
patient
immunomodulatori
drug
also
demonstr
paolo
riccio
potenza
itali
method
includ
advanc
statist
transcript
network
analysi
revers
engin
three
strategi
current
use
approach
ms
problem
modul
express
activ
matrix
metalloproteinas
choos
appropri
diet
capabl
influenc
progress
diseas
develop
new
carrier
system
target
deliveri
therapeut
agent
site
inflamm
blood
brain
barrier
symp
inflamm
genom
chairperson
peter
gar
zoltan
prohaszka
symposium
cover
whole
spectrum
differ
area
inflammatori
process
innat
recognit
regul
mhc
model
anim
paul
coussen
east
lans
usa
jerri
w
simecka
fort
worth
usa
human
diseas
take
optimist
genom
view
onto
area
may
conclud
highthroughput
method
microarray
platform
certainli
help
delin
describ
basic
rout
mechan
inflamm
howev
also
import
take
account
current
data
analysi
interpret
method
underdevelop
fulli
elucid
complex
causal
fundament
biolog
field
budapest
hungari
cliona
ofarrelli
dublin
ireland
present
import
insight
compar
genom
analysi
innat
immun
receptor
innat
immun
primari
line
activ
defens
invad
pathogen
vertebr
invertebr
initi
recognit
conserv
structur
motif
uniqu
express
microb
lectur
endr
kisstoth
sheffield
uk
present
new
data
intracellular
signal
via
tlr
contribut
improv
understand
concept
innat
sens
peter
gar
copenhagen
denmark
focus
talk
also
aspect
innat
immun
summar
recent
result
new
molecul
famili
call
ficolin
import
technic
note
made
michael
w
pfaffl
freisingweihenstephan
germani
recent
advanc
quantit
realtim
pcr
two
present
focus
infect
relat
inflamm
stephan
beck
elizabeth
hart
cambridg
uk
summar
complet
genet
epigenet
haplotyp
map
human
mhc
region
author
set
character
linkag
disequilibrium
pattern
highli
polymorph
hla
gene
background
variat
type
classic
hla
gene
common
snp
deletioninsert
polymorph
across
four
popul
sampl
analysi
provid
inform
tag
snp
captur
much
common
variat
mhc
region
could
use
diseas
associ
studi
provid
new
insight
evolutionari
dynam
ancestr
origin
hla
loci
haplotyp
tutori
biobank
network
informat
chairperson
martin
yuill
barna
vasarhelyi
increas
number
collect
contain
biolog
specimen
along
relat
experiment
clinic
data
establish
creation
larg
specimen
collect
along
data
store
lead
develop
larg
biobank
process
creat
new
opportun
also
rais
new
question
requir
appropri
action
tutori
session
provid
excel
overview
question
biobank
present
contemporari
approach
enabl
effici
adequ
use
biobankdata
genom
research
martin
yuill
manchest
uk
present
breakthrough
initi
uk
dna
bank
network
start
collat
genet
materi
collect
differ
diseas
area
wwwdnanetworkacuk
result
work
opportun
interest
applic
work
purifi
dna
specimen
standard
qualiti
known
clinic
background
unfortun
start
biobank
alway
easi
thought
rise
fall
biobank
delin
bela
melegh
hungari
barna
vasarhelyi
budapest
hungari
describ
hungarian
effort
aim
regist
current
specimen
collect
homepag
wwwbiobankhu
goal
support
creation
connect
individu
research
group
specif
homepag
common
onlin
regist
focus
clinic
genom
data
obtain
hungarian
patient
neuropsychiatr
disord
creat
month
detail
provid
special
articl
judit
maria
molnar
budapest
hungari
issu
biobank
also
rais
ethic
question
judit
sandor
budapest
hungari
gave
excel
overview
tissueissu
afternoon
session
excel
exampl
practic
applic
collect
inform
introduc
analysi
inform
requir
new
way
integr
genom
function
data
vladimir
brusic
brisban
australia
note
data
obtain
clinic
experiment
work
synthes
integr
analyz
datamin
tool
increasingli
use
last
phase
hope
provid
opportun
find
link
diseas
genom
four
lectur
tutori
focus
special
topic
bioinformat
includ
genom
data
extens
use
soren
brunak
lyngbi
denmark
present
machin
learn
approach
epitop
predict
werner
braunschweig
germani
lectur
use
